摘要
近年来,由于宫颈癌筛查的普及,全球宫颈癌发病率呈现下降趋势,约80%以上宫颈癌患者发生在发展中国家,而且年轻妇女宫颈癌的发生率在逐渐上升。对于晚期宫颈癌患者,虽然放疗和化疗有一定的疗效,但是中位生存时间也仅1年。靶向治疗在治疗晚期肿瘤方面取得了巨大的成就,临床研究已经证实贝伐单抗联合化疗可有效延长晚期宫颈癌患者的总生存时间,而且越来越多的靶向药物也被用于研究对晚期宫颈癌的治疗上。
In recent years,with the popularization of cervical cancer screening,the global incidence of cervical cancer is declining gradually.However,more than 80% of cervical cancer occurs in developing countries,and the incidence rate of cervical cancer in young women is rising.For patients with advanced cervical cancer,radiotherapy and chemotherapy have a moderate effect,but the median survival time is just one year.Targeted therapy makes great achievement in advanced cancer treatment.Clinical trials suggest that bevacizumab combined with chemotherapy effectively prolongs the overall survival time of patients with cervical cancer.On the other side,more and more targeted drugs are being used in the treatment of advanced cervical cancer.
作者
张谷裕
朱逸慜
刘崇东
曹广明
崔然
张震宇
ZHANG Gu-yu;ZHU Yi-min;LIU Chong-dong;CAO Guang-ming;CUI Ran;ZHANG Zhen-yu(Capital Medical University,Beijing Chaayang Hospital,Department of Obstetrics and Gynecology,Beijing 100069,China)
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2018年第11期1216-1220,共5页
Chinese Journal of Practical Gynecology and Obstetrics
基金
北京市医院管理局临床医学发展专项经费资助扬帆计划(ZYLX201713)
